Independent Pathways to Commercial Success for Biotech Companies
Later, leaders from Sofinnova Investments, Blueprint Medicines, BioLineRx USA, and Dynavax should have a lively discussion about Independent Pathways to Commercial Success for Biotech Companies, and look out for the panel later on Oncology's Next Frontier, featuring speakers from Loxo@Lilly, Larkspur Bioscience, AbbVie, Merck Research Laboratories, and Abdera Therapeutics, which will cover antibody-drug conjugates (ADCs), Radiopharma, and the future of cancer treatment.
After a challenging few years, biotechs are looking outside of traditional industry frameworks to not only survive but to thrive. The journey to commercial success is often a multifaceted expedition marked by innovation, resilience, and strategic decision-making. In this panel discussion, industry leaders will discuss multiple approaches that biotechs can take in order to succeed in a tumultuous market including innovative business models, disruptive technologies, market penetration and growth strategies, and overcoming regulatory hurdles that may impede success.
Moderators
Stephanie Butler
Senior Conference Production Director, Fierce Life Sciences
Stephanie Butler is a Senior Conference Production Director with Fierce Life Sciences. Previously, Ms. Butler was a Division Manager at the American Conference Institute where she was responsible for the for the creation and development of legal and business conferences in the Pharmaceutical/Life Sciences, Healthcare, Medical Technology, and Media/Advertising sectors.
Speakers
Jakob DuPont, MD
Executive Partner, Private Equity, Sofinnova Investments
Jakob Dupont brings more than two decades of experience in the field of oncology and other therapeutic areas, in developing therapies and programs dedicated to addressing high unmet medical needs. Prior to joining Sofinnova, Jakob was previously Global Head of Research & Development (R&D) and Executive Vice President at Atara Biotherapeutics.
Kate Haviland
President and Chief Executive Officer, Blueprint Medicines
Kate Haviland brings an impressive breadth of experience and leadership within the biopharmaceutical industry, as well as a substantial background in business development, portfolio strategy, investor relations and commercial execution. Since April 2022, Ms. Haviland has served as Chief Executive Officer of Blueprint Medicines.
Holly May, MBA
President, BioLineRx, USA
Holly May has served as President of BioLineRx USA since September 2022. From June 2022 to September 2022, Ms. May served as Chief Commercial Officer. Prior to joining BioLineRx, she was CCO at AVROBIO, where she was responsible for building the company’s global commercial organization inclusive of driving the development and execution of commercial strategy.
Ryan Spencer
Chief Executive Officer, Dynavax
Ryan Spencer is Chief Executive Officer of Dynavax, where he leads the company’s mission to help protect the world against infectious diseases. He first joined Dynavax in 2005 and served in positions with increasing responsibility across finance, investor relations, and corporate strategy, before becoming Senior Vice President of the commercial organization.
For more, please find the original story source here.
